Margherita Goia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Margherita Goia has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alfredo Berruti
Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia at ASST Spedali Civili, Brescia, Italy
1 shared publication - Anna Sapino
INOC - Istituto Nazionale Oncologico Candiolo; IRCCS, Candiolo, Italy
1 shared publication - Barbara Zaggia
Department of Clinical and Biological Sciences, University of Turin at San Luigi Hospital, Orbassano 10043, Turin, Italy
1 shared publication - Caterina Marchiò
Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
1 shared publication - Consuelo Buttigliero
Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, 10043 Orbassano, Italy
1 shared publication - Daniele Recupero
Department of Medical Sciences, University of Turin Turin, Italy
1 shared publication
Latest Publications
- 1 December 2015
- Published by Elsevier in Human Pathology
- Vol. 46 (12) , 1799-1807
Pitfalls in the diagnosis of adrenocortical tumors: a lesson from 300 consultation cases
- 1 December 2015
- Published by Elsevier in Human Pathology
- Vol. 46 (12) , 1799-1807
Pitfalls in the diagnosis of adrenocortical tumors: a lesson from 300 consultation cases
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 3, 129
Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues
HER2 overexpression and anti-HER2 agents represent probably the best story of success of individualized therapy in breast cancer. Due to the important therapeutic implications, the issue under the spotlight has been, since ever, the correct identification of true HER2 positivity on tissue specimens. Eligibility to anti-HER2 agents is strictly dependent on the demonstration of HER2 overexpression (by immunohistochemistry) or of HER2 gene amplification by in situ techniques (fluorescence in situ hybridization, FISH), however there are controversial issues involving cases with “equivocal” HER2 status based on conventional techniques (about 20% of specimens). In terms of HER2 expression a major debate is the presence of full-length and truncated forms of the protein and controversial clinical data have been reported on the therapeutic implications of these HER2 fragments. In terms of HER2 gene assessment, the occurrence of amplification of the chromosome 17 centromeric region (CEP17) has been proven responsible for misleading HER2 FISH results, precluding anti-HER2 based therapy to some patients. Finally HER2 activating mutations have been recently described as a biological mechanisms alternative to HER2 gene amplification. In this review we will focus on the controversies that pathologists and oncologists routinely face in the attempt to design the most tailored treatment for breast cancer patients. We will focus on the HER2 gene and on the protein, both at technical and interpretational levels.
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 3, 129
Open AccessCurrent Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues
HER2 overexpression and anti-HER2 agents represent probably the best story of success of individualized therapy in breast cancer. Due to the important therapeutic implications, the issue under the spotlight has been, since ever, the correct identification of true HER2 positivity on tissue specimens. Eligibility to anti-HER2 agents is strictly dependent on the demonstration of HER2 overexpression (by immunohistochemistry) or of HER2 gene amplification by in situ techniques (fluorescence in situ hybridization, FISH), however there are controversial issues involving cases with “equivocal” HER2 status based on conventional techniques (about 20% of specimens). In terms of HER2 expression a major debate is the presence of full-length and truncated forms of the protein and controversial clinical data have been reported on the therapeutic implications of these HER2 fragments. In terms of HER2 gene assessment, the occurrence of amplification of the chromosome 17 centromeric region (CEP17) has been proven responsible for misleading HER2 FISH results, precluding anti-HER2 based therapy to some patients. Finally HER2 activating mutations have been recently described as a biological mechanisms alternative to HER2 gene amplification. In this review we will focus on the controversies that pathologists and oncologists routinely face in the attempt to design the most tailored treatment for breast cancer patients. We will focus on the HER2 gene and on the protein, both at technical and interpretational levels.